Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study

Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon Skene, Kashfia Chowdhury, Steve Hibbert, Huw Morris, Patricia Limousin, Dilan Athauda, Camille B Carroll, Michele T Hu, Monty Silverdale, Gordon W Duncan, Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie, Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon Skene, Kashfia Chowdhury, Steve Hibbert, Huw Morris, Patricia Limousin, Dilan Athauda, Camille B Carroll, Michele T Hu, Monty Silverdale, Gordon W Duncan, Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie

Abstract

Introduction: Parkinson's disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year. The aim of this multicentre UK trial is to confirm whether these previous positive results are maintained in a larger number of participants over 2 years and if effects accumulate with prolonged drug exposure.

Methods and analysis: This is a phase 3, multicentre, double-blind, randomised, placebo-controlled trial of exenatide at a dose of 2 mg weekly in 200 participants with mild to moderate PD. Treatment duration is 96 weeks. Randomisation is 1:1, drug to placebo. Assessments are performed at baseline, week 12, 24, 36, 48, 60, 72, 84 and 96 weeks.The primary outcome is the comparison of Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3 motor subscore in the practically defined OFF medication state at 96 weeks between participants according to treatment allocation. Secondary outcomes will compare the change between groups among other motor, non-motor and cognitive scores. The primary outcome will be reported using descriptive statistics and comparisons between treatment groups using a mixed model, adjusting for baseline scores. Secondary outcomes will be summarised between treatment groups using summary statistics and appropriate statistical tests to assess for significant differences.

Ethics and dissemination: This trial has been approved by the South Central-Berkshire Research Ethics Committee and the Health Research Authority. Results will be disseminated in peer-reviewed journals, presented at scientific meetings and to patients in lay-summary format.

Trial registration numbers: NCT04232969, ISRCTN14552789.

Keywords: Parkinson-s disease; public health; qualitative research.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Outline of trial design.

References

    1. GBD 2016 Parkinson's Disease Collaborators . Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:939–53. 10.1016/S1474-4422(18)30295-3
    1. Vijiaratnam N, Evans AH. Treatment advances in Parkinson disease: same script different cast? J Clin Neurosci 2018;47:354–5. 10.1016/j.jocn.2017.10.009
    1. Vijiaratnam N, Foltynie T. Therapeutic strategies to treat or prevent off episodes in adults with Parkinson's disease. Drugs 2020;80:775–96. 10.1007/s40265-020-01310-2
    1. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896–912. 10.1016/S0140-6736(14)61393-3
    1. Htike ZZ, Zaccardi F, Papamargaritis D, et al. . Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017;19:524–36. 10.1111/dom.12849
    1. Perry T, Lahiri DK, Chen D, et al. . A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958–66. 10.1124/jpet.300.3.958
    1. Perry T, Haughey NJ, Mattson MP, et al. . Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881–8. 10.1124/jpet.102.037481
    1. Aviles-Olmos I, Limousin P, Lees A, et al. . Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136:374–84. 10.1093/brain/aws009
    1. Perry T, Lahiri DK, Sambamurti K, et al. . Glucagon-Like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603–12. 10.1002/jnr.10611
    1. Yamamoto H, Lee CE, Marcus JN, et al. . Glucagon-Like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43–52. 10.1172/JCI0215595
    1. Drucker DJ, Philippe J, Mojsov S, et al. . Glucagon-Like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434–8. 10.1073/pnas.84.10.3434
    1. Brauer R, Wei L, Ma T, et al. . Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. Brain 2020;143:3067–76. 10.1093/brain/awaa262
    1. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. . Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730–6. 10.1172/JCI68295
    1. Athauda D, Maclagan K, Skene SS, et al. . Exenatide once Weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664–75. 10.1016/S0140-6736(17)31585-4
    1. Athauda D, Gulyani S, Karnati HK, et al. . Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD trial. JAMA Neurol 2019;76:420–9. 10.1001/jamaneurol.2018.4304
    1. Crocker JC, Ricci-Cabello I, Parker A, et al. . Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ 2018;363:k4738. 10.1136/bmj.k4738
    1. Improving inclusion of under-served groups in clinical research: guidance from include project. Available:
    1. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27–44. 10.1111/j.1365-2990.1989.tb01147.x
    1. Athauda D, Maclagan K, Budnik N, et al. . Post hoc analysis of the Exenatide-PD trial-Factors that predict response. Eur J Neurosci 2019;49:410–21. 10.1111/ejn.14096
    1. Tomlinson CL, Stowe R, Patel S, et al. . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649–53. 10.1002/mds.23429
    1. Del Din S, Galna B, Godfrey A, et al. . Analysis of Free-Living Gait in Older Adults With and Without Parkinson’s Disease and With and Without a History of Falls: Identifying Generic and Disease-Specific Characteristics. Journals Gerontol - Ser A Biol Sci Med Sci 2019;74:500–6. 10.1093/gerona/glx254
    1. Del Din S, Godfrey A, Galna B, et al. . Free-living gait characteristics in ageing and Parkinson's disease: impact of environment and ambulatory bout length. J Neuroeng Rehabil 2016;13:46. 10.1186/s12984-016-0154-5
    1. Del Din S, Yarnall AJ, Barber TR, et al. . Continuous real-world gait monitoring in idiopathic REM sleep behavior disorder. J Parkinsons Dis 2020;10:283–99. 10.3233/JPD-191773
    1. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. . The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010;67:64–70. 10.1001/archneurol.2009.295
    1. Datatop: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46:1052–60. 10.1001/archneur.1989.00520460028009
    1. Olanow CW, Schapira AHV, LeWitt PA, et al. . TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5:1013–20. 10.1016/S1474-4422(06)70602-0
    1. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217–20. 10.1136/jnnp.57.2.217
    1. Thibault L, Rascol O, Corvol J-C, et al. . New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Mov Disord 2017;32:1365–70. 10.1002/mds.27055

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner